entertainment -WSS

entertainment

author：fashion 2025-10-01 07:42:07 - browse：763

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Free speech concerns arise in wake of journal editor Eisen's firing

explore

WSS

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Why scientists need input from humanists on sensitive research

FDA approves potent Eli Lilly obesity drug, Zepbound

10 million people disenrolled from Medicaid over past six months

President Biden's budget: Here's what you might have missed

Extreme heat events are a public health emergency

focus

entertainment

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare will require more price transparency from hospitals

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: CAR

Hollywood unions extend contract negotiations for actors

Pushing for an NIH office for post

Cancer drug shortages should be causing more outrage

Study: New antibiotic targets gonorrhea as well as last existing drug

Medical records are filled with copy

FDA approves potent Eli Lilly obesity drug, Zepbound

focus

EPA limits use of carcinogenic gas for sterilizing medical devices

As AI in medicine takes off, can 'human in the loop' prevent harm?

Steward Health Care Massachusetts hospitals face fiscal disaster

President Biden's budget: Here's what you might have missed

Will General Catalyst be the first of many hospital takeovers?

Just how powerful is the placebo effect?

entertainment

explore

Wikipedia

entertainment